Partner Headlines - MDVN

  1. Newly Profitable Medivation Riding High On Drug Sales

    IBD
  2. Chip Stocks, Biotechs Lead Another Nasdaq Rally

    IBD
  3. Major Upgrades And Downgrades In Friday's Market Action

    Benzinga
  4. Medivation Hits High After Q3 Earnings Beat

    IBD
  5. Medivation Hits High After Q3 Earnings Beat

    IBD
  6. Medivation and Astellas Announce Phase 3 Study of Enzalutamide ...

    GuruFocus
  7. J&J Earnings Beat; Olysio Chatter Hits Gilead

    IBD
  8. Consider Medivation for Your Portfolio

    FoxBusiness
  9. Benzinga's Top Downgrades

    Benzinga
  10. Goldman Sachs Downgrades Medivation To Neutral, Shares Drop

    Benzinga
  11. These 3 Biotech Stocks Just Hit New Highs

    Benzinga
  12. Fast Money Halftime Report Final Trade From September 12

    Benzinga
  13. Medivation Eyes Blockbuster As Cancer Drug Gets An OK

    IBD
  14. Stifel Raises Medivation Inc Price Target

    Benzinga
  15. Stocks Hitting 52-Week Highs

    Benzinga
  16. A Few Reasons Why Investors Should Consider Dendreon for Their ...

    GuruFocus
  17. Medivation Cancer Drug Fuels Beat, Swings To Profit

    IBD
  18. Benzinga's Volume Movers

    Benzinga
  19. Medivation Announces Change in Executive Management Team; Dawn ...

    Benzinga
  20. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  21. Aegis Capital Believes Seragon Deal Underscores Value In Medivation

    Benzinga
  22. UPDATE: Stifel Reiterates On Medivation Following Prostate Cancer ...

    Benzinga
  23. Benzinga's Top Upgrades

    Benzinga
  24. US Stock Futures Flat Ahead Of International Trade Data

    Benzinga
  25. UPDATE: Canaccord Genuity Initiates Coverage on Medivation as ...

    Benzinga
  26. Morning Market Movers

    Benzinga
  27. Stocks To Watch For April 1, 2014

    Benzinga
  28. Celegene, Pharmacyclics Lead Biotech Short Interest Trend (CELG, ...

    Benzinga
  29. UPDATE: Astellas Announces Marketing Approval in Japan for XTANDI® ...

    Benzinga
  30. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, ...

    Benzinga
  31. Market Wrap For February 28: Markets Unable To Hold On To Gains

    Benzinga
  32. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE ...

    Benzinga
  33. Benzinga's Top #PreMarket Losers

    Benzinga
  34. 2 Deaths, 25% Plunge -- And Still A Big Upside

    YCharts
  35. Mid-Afternoon Market Update: Fed Will Continue the Taper in February

    Benzinga
  36. Mid-Day Market Update: Yahoo! Slips After Q4 Results; RF Micro ...

    Benzinga
  37. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga
  38. Mid-Morning Market Update: Markets Open Lower; Dow Chemical Posts ...

    Benzinga
  39. Stocks Hitting 52-Week Highs

    Benzinga
  40. Benzinga's Top #PreMarket Gainers

    Benzinga
  41. Medivation and Astellas Announce Final Results From the Phase ...

    Benzinga
  42. UPDATE: Aegis Capital Reiterates on Medivation Following In-Line ...

    Benzinga
  43. Medivation, Astellas Announce Phase 3 PREVAIL Trial of Enzalutamide ...

    Benzinga
  44. Uh Oh: Is This Cancer Highflyer In Your Account?

    YCharts
  45. Worse-Than-Expected Xtandi Sales Hitting Shares of Medivation; ...

    Benzinga
  46. Medivation Elects Kathryn Falberg to Board of Directors

    Benzinga
  47. Medivation Bulls Load Up on Call Options

    SchaeffersResearch
  48. Aegis Capital Corp. Reiterates Buy Rating, $100 PT on Medivation

    Benzinga
  49. Medivation, Inc. (MDVN) President and CEO David Hung sells 1 ...

    GuruFocus
  50. Benzinga's Top Initiations

    Benzinga
  51. Celgene, Regeneron Pharmaceutical Lead Biomed Group

    IBD
  52. Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence ...

    GuruFocus
  53. UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Medivation

    Benzinga
  54. Medivation Effects 2-for-1 Stock Split

    Benzinga
  55. Three Biotech Stocks Analysts Are Keen On (MDVN, GEVA, OPTR)

    Benzinga
  56. US FDA Approves XTANDI for Patients With Metastatic Castration-Resistant ...

    Benzinga
  57. Medivation Reports 2-for-1 Forward Split of Common Stock

    Benzinga
  58. Andreas Halvorsen Buys 2 Million Shares of Medivation

    GuruFocus
  59. Medivation Inc. (MDVN) President and CEO David Hung sells 25, ...

    GuruFocus
  60. Medivation Inc. (MDVN) Chief Business Officer and CFO Clarence ...

    GuruFocus
  61. Stocks Hitting 52-Week Highs

    Benzinga
  62. Health Care Sector Wrap

    FoxBusiness
  63. Four Winning Trades Based on Analyst Calls

    Benzinga
  64. Medivation Bull Looks to Cash In on Continued Rally

    SchaeffersResearch
  65. Analyst Upgrades: MDVN, SCHN, and STI

    SchaeffersResearch
  66. UPDATE: Wedbush Reiterates Outperform Rating, Raises PT for Medivation

    Benzinga
  67. Citigroup Reiterates Buy Rating, $129 PT for Medivation

    Benzinga
  68. Medivation and Astellas Announce Enzalutamide Data

    Benzinga
  69. Crazy Action in Medivation After Negative StreetSweeper Post

    Benzinga
  70. Global Fears and Small Caps: How Much of an Impact?

    Benzinga
  71. Social Media Outlook for Tuesday 15 (DKS, MDVN, BBY, ACOM)

    Benzinga
  72. GlaxoSmithKline, Vertex Point To Biotech Strength

    IBD
  73. UPDATE: Wedbush Reiterates Outperform Rating, Raises PT for Medivation

    Benzinga
  74. Will Johnson & Johnson Cure Cancer?

    Benzinga
  75. Options Players Show a Preference for Medivation Puts

    SchaeffersResearch
  76. Notable Put Options Activity in Medivation

    Benzinga
  77. Weekly CFO Sells Highlight: SLCA, UNH, LVS, RATE, MDVN, YUM, ...

    GuruFocus
  78. Medivation's Stellar Technical Performance Entices Option Bulls

    SchaeffersResearch
  79. Benzinga's M&A Chatter for Wednesday February 1, 2012

    Benzinga
  80. Medivation Soars on Phase III Trial Data; Stock Up 21%

    Benzinga
  81. Jefferies Raises PT on Medivation to $95

    Benzinga
  82. Wedbush Raises PT on Medivation to $81

    Benzinga
  83. Medivation and Astellas Announce Positive Results From the Phase ...

    Benzinga
  84. Upgrades & Downgrades: AZO, MDVN, POT, TSLA, and UA

    SchaeffersResearch
  85. Gilead, Celgene Join Big Pharma On M&A Front

    IBD
  86. Alzheimer's drug test halted

    IBD
  87. Best Biotech Stocks of 2011

    Benzinga
  88. Options Players Get Bearish with Medivation Puts

    SchaeffersResearch
  89. Notable Put Options Activity in Medivation

    Benzinga
  90. Put Volume Heats Up as Medivation Surges to a New High

    SchaeffersResearch
Trading Center